CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Total Current Liabilities

Last Annual Value

3.88M

3-Year CAGR

10%

5-Year CAGR

18%

10-Year CAGR

5%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Total Current Liabilities

CRVO · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
3.88M
14.3%5.8%-1.3% 
28.58M
14.5%19.1%N/A
49.74M
-16.3%-13.2%-1.3%
4.63M
-42.8%5.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
21.53M
3.7%5.7%-14.1%
CLNN logo
Clene Inc.
NASDAQ:CLNN
10.78M
-24.8%12.3%N/A
36.15M
23.1%24.9%N/A
9.01M
15.0%8.2%37.0%
10.11M
39.5%118.7%N/A
11.41M
-6.6%-1.4%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
21.56M
16.3%14.9%13.8%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5